Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the long-term use of RU58841 for hair loss, with users sharing their experiences and seeking information on its effectiveness and whether it needs to be used continuously like minoxidil or finasteride.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

A user experiencing hair loss since age 18 is considering switching from finasteride and minoxidil to dutasteride after poor results and lifestyle choices. They plan to improve their lifestyle and get blood work done to assess treatment effectiveness.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

For male pattern baldness in Orange County, treatments include 2.5mg of dutasteride daily, oral minoxidil 2.5mg twice daily, and derma stamping. Users discuss the effectiveness of these treatments and seek recommendations for clinics and techniques.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

A user's experience with treating their hair loss using finasteride, minoxidil, RU58841, dermarolling, and nizoral; specifically discussing dosage levels of the medications and effects on libido.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation is about the effectiveness of Ultrax Labs Hair Surge Caffeine Hair Loss Hair Growth Stimulating Shampoo, with the original poster questioning if the positive reviews are genuine or not. No specific treatments were discussed.

A new trial for Verteporfin to treat hair loss will start in LA, led by Dr. Behnam. Users are hopeful it could be a breakthrough treatment.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A user visited a dermatologist for hair loss and was prescribed Minoxidil without a physical examination, leading to skepticism about the thoroughness of the appointment. The user is considering seeking a second opinion due to the lack of tests or physical checks.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. It also mentions the importance of raising vitamin D3 levels.